Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2006;48:979-987
Published online before print September 18, 2006, doi: 10.1161/01.HYP.0000242331.99369.2f
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
48/5/979    most recent
01.HYP.0000242331.99369.2fv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cheng, X. W.
Right arrow Articles by Yokota, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cheng, X. W.
Right arrow Articles by Yokota, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Heart Failure
*High Blood Pressure
Related Collections
Right arrow Congestive
Right arrow Remodeling
Right arrow Animal models of human disease
Right arrowRelated Article

(Hypertension. 2006;48:979.)
© 2006 American Heart Association, Inc.


Original Articles

Elastolytic Cathepsin Induction/Activation System Exists in Myocardium and Is Upregulated in Hypertensive Heart Failure

Xian Wu Cheng; Koji Obata; Masafumi Kuzuya; Hideo Izawa; Kae Nakamura; Eri Asai; Tetsuro Nagasaka; Masako Saka; Takahiro Kimata; Akiko Noda; Kohzo Nagata; Hai Jin; Guo-Ping Shi; Akihisa Iguchi; Toyoaki Murohara; Mitsuhiro Yokota

From the Department of Cardiovascular Genome Science (X.W.C., K.O., M.S., M.Y.), Nagoya University School of Medicine, Nagoya, Japan; Departments of Geriatrics (X.W.C., M.K., K.N., E.A., H.J., A.I.), Cardiology (H.I., T.M.), and Clinical Pathophysiology (T.N.), Nagoya University Graduate School of Medicine, Nagoya, Japan; the Department of Medical Technology (T.K., A.N., K.N.), Nagoya University School of Health Sciences, Nagoya, Japan; the Department of Cardiovascular Medicine (G.-P.S.), Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass; and the Department of Cardiology (X.W.C., H.J.), College of Medical, Yanbian University, Yanji, Jilin Province, China.

Correspondence to Xian Wu Cheng, Department of Cardiovascular Genome Science, Nagoya University School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan. E-mail xianwu{at}med.nagoya-u.ac.jp

Cathepsins are cysteine proteases that participate in various types of tissue remodeling. However, their expressions during myocardial remodeling have not been examined. In this study, we investigated their expressions in the left ventricular (LV) myocardium of rats and humans with hypertension-induced LV hypertrophy or heart failure (HF). Real-time PCR and immunoblot analysis revealed that the abundance of cathepsin S mRNA or protein in the LV tissues was greater in rats or humans with HF than in those with hypertrophy or in control subjects. Immunostaining showed that cathepsin S was localized predominantly to cardiac myocytes and coronary vascular smooth muscle cells, but also overlapped in part with macrophages. Elastic lamina fragmentations significantly increased in the LV intramyocardial coronary arteries of HF rats. The amount of elastolytic activity in the extract of the LV myocardium was markedly increased for HF rats compared with controls, and this activity was mostly because of cathepsin S. Although the amount of elastin mRNA was increased in the LV myocardium of HF rats, the area of interstitial elastin was not. The expression of interleukin 1ß was increased in the LV myocardium of HF rats, and this cytokine was found to increase the expression and activity of cathepsin S in cultured neonatal cardiomyocytes. These results suggest that cathepsin S participates in pathological LV remodeling associated with hypertension-induced HF. This protease is, thus, a potential target for therapeutics aimed at preventing or reversing cardiac remodeling.


Key Words: myocardial remodeling • hypertension • heart failure • cysteine proteases • cardiac myocytes


Related Article:

Digesting the Remodeled Heart: Role of Lysosomal Cysteine Proteases in Heart Failure
Flora Sam and Deborah A. Siwik
Hypertension 2006 48: 830-831. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
X. W. Cheng, T. Murohara, M. Kuzuya, H. Izawa, T. Sasaki, K. Obata, K. Nagata, T. Nishizawa, M. Kobayashi, T. Yamada, et al.
Superoxide-Dependent Cathepsin Activation Is Associated with Hypertensive Myocardial Remodeling and Represents a Target for Angiotensin II Type 1 Receptor Blocker Treatment
Am. J. Pathol., August 1, 2008; 173(2): 358 - 369.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Novinec, R. N. Grass, W. J. Stark, V. Turk, A. Baici, and B. Lenarcic
Interaction between Human Cathepsins K, L, and S and Elastins: MECHANISM OF ELASTINOLYSIS AND INHIBITION BY MACROMOLECULAR INHIBITORS
J. Biol. Chem., March 16, 2007; 282(11): 7893 - 7902.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
F. Sam and D. A. Siwik
Digesting the Remodeled Heart: Role of Lysosomal Cysteine Proteases in Heart Failure
Hypertension, November 1, 2006; 48(5): 830 - 831.
[Full Text] [PDF]